StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Stock analysts at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

MRNS has been the subject of several other reports. HC Wainwright reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday, September 23rd. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, Cantor Fitzgerald decreased their target price on Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $6.07.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $0.33 on Friday. The stock has a market capitalization of $18.44 million, a price-to-earnings ratio of -0.13 and a beta of 1.26. Marinus Pharmaceuticals has a one year low of $0.26 and a one year high of $11.26. The company’s 50-day simple moving average is $1.33 and its 200-day simple moving average is $1.35.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The business had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter last year, the firm posted ($0.61) EPS. As a group, research analysts forecast that Marinus Pharmaceuticals will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MRNS. abrdn plc grew its stake in shares of Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares during the period. Avoro Capital Advisors LLC grew its position in Marinus Pharmaceuticals by 31.4% in the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after acquiring an additional 990,607 shares during the period. GSA Capital Partners LLP raised its stake in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals during the second quarter valued at $813,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at $727,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.